Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis Tan YV; Waschek JAASN Neuro 2011[Oct]; 3 (4): äMS (multiple sclerosis) is a chronic autoimmune and neurodegenerative pathology of the CNS (central nervous system) affecting approx. 2.5 million people worldwide. Current and emerging DMDs (disease-modifying drugs) predominantly target the immune system. These therapeutic agents slow progression and reduce severity at early stages of MS, but show little activity on the neurodegenerative component of the disease. As the latter determines permanent disability, there is a critical need to pursue alternative modalities. VIP (vasoactive intestinal peptide) and PACAP (pituitary adenylate cyclase-activating peptide) have potent anti-inflammatory and neuroprotective actions, and have shown significant activity in animal inflammatory disease models including the EAE (experimental autoimmune encephalomyelitis) MS model. Thus, their receptors have become candidate targets for inflammatory diseases. Here, we will discuss the immunomodulatory and neuroprotective actions of VIP and PACAP and their signalling pathways, and then extensively review the structure-activity relationship data and biophysical interaction studies of these peptides with their cognate receptors.|Animals[MESH]|Humans[MESH]|Immunologic Factors/chemistry/metabolism/*therapeutic use[MESH]|Multiple Sclerosis/metabolism/*therapy[MESH]|Pituitary Adenylate Cyclase-Activating Polypeptide/chemistry/metabolism/therapeutic use[MESH]|Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/*metabolism[MESH]|Signal Transduction/drug effects/*physiology[MESH]|Structure-Activity Relationship[MESH]|Vasoactive Intestinal Peptide/chemistry/metabolism/*therapeutic use[MESH] |